Regulatory approval
Published by the Health Canada.
Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.
This is written in the approval document as:
LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.
Citation
AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type |
Biomarker(s) |
Cancer type |
Therapy(ies) |
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
Ovarian Epithelial Tumor |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
Ovarian Epithelial Tumor |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
Ovarian Epithelial Tumor |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
Ovarian Epithelial Tumor |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
Peritoneal Serous Carcinoma |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
Peritoneal Serous Carcinoma |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
Peritoneal Serous Carcinoma |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
Peritoneal Serous Carcinoma |
Bevacizumab,
Olaparib
|
|